Rheumatology

Back to articles

Registry data indicate rituximab safe and effective for SLE

KEY POINT

A prospective analysis of the French Autoimmunity and Rituximab (AIR) registry showed that rituximab (Rituxan—Genentech; Biogen Idec) was satisfactorily tolerated and had clinical efficacy in systemic lupus erythematosus (SLE) patients. Efficacy results from the AIR registry are similar to data analyses from open-label trials, but contrary to analyses from randomized, placebo-controlled trials.

SOURCES

Terrier B et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry. Arthritis Rheum. 2010;62:2458–66.

Merrill JT, Buyon JP. Rituximab: wanted dead or alive… [editorial]. Arthritis Rheum. 2010;62:2188–91.

Recent Articles